Abstract
dc:description.abstract<b>Objective</b><br></br>DDLPS is characterized by the amplification of MDM2, CDK4 and HMGA2. Targeted therapies directed to these alterations resulted in mixed results. This study aimed at i) unravelling whether well differentiated liposarcoma (WDLPS) undergo a progressive evolution to dedifferentiated liposarcoma (DDLPS) through the analysis of the transcriptomic profile of retroperitoneal liposarcoma; ii) identifying and validating therapeutic targets for DDLPS including the primary oncogenic drivers MDM2 and CDK4 and secondary alterations identified in the transcriptomic analysis exploiting in-house generated patient-derived DDLPS tumor models; iii) testing the activity of combined treatment with chemotherapy and targeted therapeutics. <br></br><br></br> <b>Methods</b><br></br> In a contemporary retrospective series of primary retroperitoneal DDLPS and WDLPS (N=107), we sampled paired DD/WD/normal fat (NF) components of DDLPS and paired WD/NF components of WDLPS. RNA-Seq data were normalized using the trimmed mean of M-value (TMM) algorithm, heteroscedasticity was removed, and differential expression analysis (DEA) performed. Gene sets enrichment analysis (GSEA) evaluated enrichment in biological hallmarks and was performed to overcome FDR correction of DEA and evaluate the ensemble. FDR threshold 0.05 was considered for significance. We generated a library of 15 patient-derived xenograft (PDX) from untreated primary DDLPS and three 2D cell lines, which are marked by amplification of MDM2, CDK4 and HMGA2 genes and characterized by a different array of histological dedifferentiation lineages as well as levels of amplification of the liposarcoma driver genes. Three of these PDXs (LS-BZ, LS-NV and LS-MP) and the cell lines were exploited to functionally validate therapeutic targets identified at RNA-seq analysis and comparatively evaluate the effectiveness of chemotherapeutics with an indication in soft tissue sarcoma. <br></br><br></br> <b>Results</b><br></br> Marked transcriptional changes exist among paired components of DDLPS (DD, WD, NF) or WDLPS (WD, NF). GSEA analysis highlighted deregulation in hallmarks. An upregulation of G2M checkpoint and mitotic spindle gene sets was observed when WD components of DDLPS was compared to WDLPS and progressively increase in the DD component. Some targetable genes from the leading edge of these pathways (AURKA, CHK1, and EZH2) as well as the primary oncogenic drivers (MDM2, CDK4, and HMGA2) of liposarcoma were functionally validated with targeted agents in cell lines of DDLPS, showing a variable extent of anti-cancer activity as a function of the cell model. As a further validation, these druggable targets were tested in vivo and compared with chemotherapeutics administered as single agent. PDX models LS-NV and LS-MP were MDM2-amplified and consistently recapitulate the morphology and transcriptomic profile of their paired clinical tumors. Cabazitaxel and ifosfamide resulted in the highest maximum tumor volume inhibition. MDM2 inhibition with milademetan resulted in different effects in the two analyzed models, which were higher in LS-MP compared to LS-NV. Conversely, the AURKA inhibitor prexasertib resulted in a higher mTVI% in the LS-NV compared to the LS-MP model. <br></br><br></br> Considering the small benefit of single-agent treatment against DDLPS, we hypothesize that combination therapies may have greater effectiveness. Following results on the XPO1 inhibitor achieved before this PhD project, we tested the hypothesis that combination of selinexor and either trabectedin or lurbinectedin can impact tumor growth in DDLPS PDX. This hypothesis was supported by clinical evidence of a benefit after re-challenge to trabectedin following selinexor in two patients. We designed in-vivo experiments on PDXs of DDLPS to investigate the activity of a sequential treatment with trabectedin/luribinectedin plus selinexor or their combination. The histomorphological and molecular characteristics of PDXs of DDLPS (LPS-BZ and LPS-NV) were confirmed to reproduce the clinical tumor. In the PDX model (LPS-BZ) with the faster growth rate (doubling time: 5 days), the sequence of selinexor followed by trabectedin was more effective than each single-agent. A further experiment was conducted in a second PDX model (LPS-NV) characterized by a slower growth rate (doubling time: 12 days) and results consistently showed a greater activity for the selinexor and trabectedin sequence compared to selinexor or trabectedin alone. Finally, we tested lurbinectedin instead of trabectedin in the LPS-NV model, where selinexor and lurbinectedin showed a greater anti-tumor effect compared to either single agent. <br></br><br></br> <b>Conclusions</b><br></br> We identified and validated therapeutic targets for DDLPS beyond the oncogenic drivers of this disease and a treatment combination for DDLPS. These results have implications to identify treatment strategies to be tested in new in vivo experiments to prioritize new treatment strategies for clinical trials.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Pasquali, Sandro
Rights
- Language dc:language
- en